Cytokinetics Sees Omecamtiv Potential In Certain Heart Failure Patients
The Company And Amgen Continue To Analyze GALACTIC-HF Results
Cytokinetics highlighted a greater benefit from omecamtiv mecarbil treatment in patients with lower LVEF • Source: Shutterstock 
